The estimated Net Worth of Jeff Goater is at least $4.47 Million dollars as of 21 July 2021. Mr. Goater owns over 127,778 units of Surface Oncology Inc stock worth over $138,268 and over the last 9 years he sold SURF stock worth over $2,694,446. In addition, he makes $1,642,260 as President, Chief Executive Officer, and Director at Surface Oncology Inc.
Sign up
Mr. Goater SURF stock SEC Form 4 insiders trading
J has made over 6 trades of the Surface Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 127,778 units of SURF stock worth $779,446 on 21 July 2021.
The largest trade he's ever made was selling 250,000 units of Surface Oncology Inc stock on 10 June 2021 worth over $1,915,000. On average, J trades about 20,673 units every 28 days since 2016. As of 21 July 2021 he still owns at least 129,222 units of Surface Oncology Inc stock.
You can see the complete history of Mr. Goater stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
J. Jeffrey Goater biography
J. Jeffrey Goater is President, Chief Executive Officer, Director of the Company. Mr. Goater previously served as our Secretary from February 2017 to September 2018, and as our Chief Business Officer from February 2017 to February 2018. Prior to Surface, Mr. Goater served as the Chief Financial Officer and held other senior business and finance positions at Voyager Therapeutics, Inc., from September 2013 to December 2016. Prior to that, he served as Vice President of Business Development at Synageva BioPharma Corp. (now Alexion Pharmaceuticals, Inc.), from April 2013 to July 2013, and prior to that, he worked as an investment banker at Evercore Partners Inc. (now Evercore Inc.), from April 2008 to April 2013, most recently as Managing Director. Prior to that, Mr. Goater worked as an equity research analyst at Cowen and Company, LLC, covering the biopharmaceutical sector, from August 2004 to March 2008. He also currently serves on the board of directors of Vaccinex, Inc., a publicly traded biotechnology company. Mr. Goater received a B.A. in Biology, an M.S. in Pathology, an M.S. in Microbiology and Immunology, and an M.B.A., all from the University of Rochester. Our Board of Directors believes that Mr. Goater’s experience as our Chief Executive Officer, as well as his experience in the life science industry, qualifies him to serve on our Board of Directors.
What is the salary of J Goater?
As the President, Chief Executive Officer, and Director of Surface Oncology Inc, the total compensation of J Goater at Surface Oncology Inc is $1,642,260. There are no executives at Surface Oncology Inc getting paid more.
How old is J Goater?
J Goater is 44, he's been the President, Chief Executive Officer, and Director of Surface Oncology Inc since 2018. There are 16 older and no younger executives at Surface Oncology Inc. The oldest executive at Surface Oncology Inc is Elliott Sigal, 68, who is the Independent Director.
What's J Goater's mailing address?
Jeff's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.
Insiders trading at Surface Oncology Inc
Over the last 7 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.
What does Surface Oncology Inc do?
surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww
What does Surface Oncology Inc's logo look like?
Complete history of Mr. Goater stock trades at Voyager Therapeutics Inc, Surface Oncology Inc, Vaccinex Inc, and ContextLogic Inc
Surface Oncology Inc executives and stock owners
Surface Oncology Inc executives and other stock owners filed with the SEC include:
-
J. Jeffrey Goater,
President, Chief Executive Officer, Director -
Vito Palombella,
Chief Scientific Officer -
Robert Ross,
Chief Medical Officer -
J. Jeffrey Goater,
CEO, Pres & Director -
Dr. Robert W. Ross,
Chief Medical Officer -
Daniel Lynch,
Executive Chairman of the Board -
Laurie Stelzer,
Independent Director -
Cameron McDonough,
Independent Director -
Armen Shanafelt,
Independent Director -
David Grayzel,
Independent Director -
Elliott Sigal,
Independent Director -
Ramy Ibrahim,
Independent Director -
Liisa Nogelo,
Chief Legal Officer, Secretary -
Wendy Dwyer,
Chief Business Officer -
Jessica Fees,
Principal Financial Officer, Principal Accounting Officer, Senior Vice President, Finance and Treasurer -
Alison O'Neill,
Sr. VP of Clinical Devel. -
Bob Steininger,
Sr. VP of Chemistry, Manufacturing & Controls -
Lisa McGrath,
Sr. VP of HR -
Liisa I. Nogelo,
Sec., Chief Compliance Officer & Chief Legal Officer -
Jessica Fees,
Sr. VP of Fin. & Treasurer -
Carsten Brunn,
Director -
Theresa Boni,
General Counsel & Secretary -
Enterprise Associates 14, L...,
-
Ravi Viswanathan,
10% owner -
Scott D Sandell,
10% owner -
Patrick J Kerins,
10% owner -
Forest Baskett,
10% owner -
M James Barrett,
10% owner -
Institutes For Bio Medical ...,
-
Venture Fund Ix, L.P.Atlas ...,
-
Management Group, Llc Lilly...,
-
Peter W. Sonsini,
10% owner -
David M Mott,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Peter J Barris,
10% owner -
Enterprise Associates 14, L...,
10% owner -
2017 Liquidating Trust Kear...,
-
Llc Fmr,
-
Ltd Fil,
-
Geoff Mcdonough,
Director -
Capital, Llc Eco R1,
10% owner -
Alison Oneill,
Chief Medical Officer -
Henry C. Rath,
Chief Business Officer -
Denice Torres,
Director -
Benjamin Hickey,
Director -
Chandra Adams,
Deputy GC